An excess ofthe tryptophan metabolite quinolinic acid in the brain has been hypothetically related to the pathogenesis of Huntington disease. Quinolinate's immediate biosynthetic enzyme, 3-hydroxyanthranilate oxygenase (EC 1.13.11.6), has now been detected in human brain tissue. The activity of 3-hydroxyanthranilate oxygenase is increased in Huntington disease brains as compared to control brains. The increment is particularly pronounced in the striatum, which is known to exhibit the most prominent nerve-cell loss in Huntington disease. Thus, the Huntington disease brain has a disproportionately high capability to produce the endogenous "excitotoxin" quinolinic acid. This rmding may be of relevance for clinical, neuropathologic, and biochemical features associated with Huntington disease.
Over the past several years, there has been remarkable progress in elucidating details of the genetic features of Huntington disease (HD) (1) (2) (3) . However, the molecular mechanisms underlying the pathogenesis of selective neuronal loss in HD remain unidentified. One current hypothesis that has received considerable interest and investigative attention assumes that a pathological overabundance of an endogenous excitatory amino acid ("excitotoxin") in the brain is causally related to the occurrence of neurodegeneration in HD (4, 5) . Of the excitotoxins considered so far, quinolinic acid figures most prominently. Quinolinate has been recognized for decades as a peripheral tryptophan metabolite (6, 7) and has recently been found to exist in brain tissue and human cerebrospinal fluid (5, 8) . Lesions produced by intrastriatal injections of quinolinate in rats duplicate neuropathological and neurochemical changes that are characteristic for HD. For example, in both HD caudate and in quinolinate-injected rat striatum, there is a substantial reduction in the number of y-aminobutyratergic (GABAergic) and cholinergic neurons but survival of medium-size Golgi type II neurons (containing somatostatin, neuropeptide Y, and NADPH diaphorase) and striatal afferents (5, (9) (10) (11) .
The conversion of tryptophan to quinolinate via the kynurenine pathway (6, 7, 12, 13) has not so far been demonstrated in cerebral tissue (14 (15, 16) . To date, only sporadic attention has been paid to the existence of the kynurenine pathway in the human brain. In addition to our recent report on QPRTase (17), we have now ascertained the presence and have examined the regional distribution of 3-HAOxase in brain tissue from patients who died without neurological disease and from individuals who died with HD. (16) . The stability of 3-HAOxase activity under similar storage and freezing/thawing conditions was ascertained in preliminary experiments with rat brain tissue (16) . For glutamate decarboxylase determination, the original homogenate was further diluted (1:5) with 50 mM Tris HCI buffer (pH 7.4) containing 0.2% (vol/vol) Triton X-100, and 25-,l samples were used for enzyme measurement (9) . Protein content was determined in the original homogenate by the method of Lowry et al. (19) with bovine serum albumin as a standard.
MATERIALS AND METHODS
Twenty-four control brains and 25 HD brains were used in the study. The demographic characteristics of the individuals studied (mean age, 64.6 years for controls and 67.8 years for HD patients; male/female ratio, 22/2 for controls and 12/13 for HD patients), as well as the intervals between occurrence of death and time of freezing of the tissue (mean, 5.5 hr for controls and 7.2 hr for HD patients), were recorded and considered for statistical comparisons of the two groups. HD brains were graded between 2 and 4 (average 2.7) according to the neuropathological scale of Vonsattel et al. (20) . The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
gional variability among 11 different brain regions studied. The enzymatic product, quinolinate, was identified in control caudate tissue in separate experiments using nonradioactive 3-hydroxyanthranilic acid as a substrate under otherwise standard assay conditions. The extent of conversion to quinolinate (determined radioenzymatically; ref. 21) was identical to that observed in routine radiochemical 3-HAOxase assays. In control brains, cerebral cortical regions contained one-fourth to one-sixth as much 3-HAOxase as the substantia nigra, the region with the highest enzyme activity (Table 1) . Statistical analysis of control brain tissue revealed no significant correlation between caudate 3-HAOxase activity and the gender and age of the brain donor or postmortem interval (discriminate analysis and logistic regression). HD brains showed significant increases in 3-HAOxase activity in most brain regions. The increase in 3-HAOxase was found to be particularly pronounced in the striatum, reaching increments of + 370%o in the caudate nucleus and + 360%o in the putamen. No correlation was discerned between the neuropathological grade and the enzyme activity in caudate nuclei from HD brains. (24) . Our findings also concur with data from rat striatal lesions, which indicate a severalfold increase in local 3-HAOxase activity Proc. Natl. Acad. Sci. USA 85 (1988) Proc. Natl. Acad. Sci. USA 85 (1988) 4081 within days after experimentally induced loss of nerve cells (25) . Thus, elevated levels of 3-HAOxase in the animal model are likely to be related to the proliferation of astrocytes containing this enzyme.
It is possible that the increase in 3-HAOxase activity in HD brains, too, is at least in part a reflection of the astrogliosis known to occur in diseased tissue (26) . Thus, particularly pronounced enzyme changes were observed in the striatum. However, significant increases in 3-HAOxase activity also occurred in areas where there is less atrophy, and no correlation was found between the severity of neurodegeneration and the increments in 3-HAOxase activity. These findings indicate that unrecognized mechanisms of 3-HAOxase regulation might contribute to the enhanced ability of HD brains to produce quinolinate. Genetic factors may play a role; the idea of a genetically determined increase in the levels of an endogenous excitotoxin in the brain is concordant with recent discoveries on the molecular biology of HD (1-3) . However, the lack of a significant change in 3-HAOxase activity in the medulla, for example, is not easy to reconcile with the notion that a genetic aberration related to 3-HAOxase function is responsible for the increase in 3-HAOxase activity described here; such an abnormality should probably be expressed equally in all brain cells.
The (2, 5) are taken into account, only modest elevations of quinolinate levels-which possibly undergo intermittent variations and may be under the influence of nutritional factorsare to be expected. Such marginal increases are unlikely to be amenable to direct analytical assessment. Indeed, no changes in the concentration of quinolinate in urine (27) or in cerebrospinal fluid (28) have been detected in HD samples.
The demonstration of the human brain's ability to produce quinolinate also provides a basis for the investigation of the quinolinate system in neurological disorders other than HD. Since quinolinate is an agonist at the N-methyl-D-aspartate receptor (29, 30) , a site that is suspected to play a role in the pathogenesis of several neurodegenerative conditions (31) , a thorough examination of 3-HAOxase and other elements of the cerebral kynurenine pathway could reveal clues regarding the etiology of nerve-cell loss in temporal-lobe epilepsy, cerebral ischemia, hypoglycejnia, or the normal aging process (32) . Furthermore, it is possible that pharmacological agents that interfere with quinolinate production in the brain may be of therapeutic value for the prevention or arrest of the neurodegenerative process.
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